LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
IPO Year:
Exchange: NASDAQ
Website: livanova.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/20/2025 | $60.00 | Peer Perform → Outperform | Wolfe Research |
| 2/26/2025 | Outperform → Peer Perform | Wolfe Research | |
| 10/4/2024 | $65.00 | Buy | Goldman |
| 9/17/2024 | $55.00 → $66.00 | Neutral → Outperform | Robert W. Baird |
| 3/20/2024 | Buy | Needham | |
| 2/20/2024 | $60.00 → $70.00 | Neutral → Buy | Mizuho |
| 9/6/2023 | $52.00 | Hold | HSBC Securities |
| 7/19/2023 | $56.00 | Neutral | Robert W. Baird |
| 4/14/2023 | $48.00 | Neutral | Mizuho |
| 12/21/2022 | $62.00 | Equal Weight | Barclays |
Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced completion of the CORE-VNS study, evaluating comprehensive outcomes of real-world evidence for more than 800 people with epilepsy treated with VNS Therapy™ worldwide. With the clinical study report (CSR) now complete, the final 36-month data further validate the effectiveness of VNS Therapy for severe focal seizures in both children and adults with drug-resistant epilepsy (DRE) and demonstrate early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures. "It is c
This is the latest prospective evaluation of VNS Therapy in generalized tonic-clonic seizures Findings include 77% median seizure reduction and 43% of participants reporting seizure freedom at 24-month visits LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with drug-resistant epilepsy (DRE) from the CORE-VNS three-year study have been published in Epilepsia1. Several CORE-VNS study findings were highlighted in the recent article on GTC seizures in DRE patients who received VNS Therapy™, including: At 12 months, the median reduction in GTC seizure frequency was 74%, and t
Final critical papers on RECOVER clinical study data accepted, supporting the Company's submission for coverage reconsideration Strong 24-month top-line data for RECOVER clinical study demonstrates durability of VNS Therapy In-depth analysis on suicidality at 12 months yields positive results LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it has initiated the process with the U.S. Centers for Medicare and Medicaid Services (CMS) to seek reconsideration of national Medicare coverage for VNS Therapy™ in unipolar patients with treatment-resistant depression (TRD). The first step in the process for making a National Coverage Determination (NCD)
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The presentation will take place Thurs., June 5, at 3:10 p.m. Eastern Time. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the webcast. A replay will be available on the LivaNova website within 24 hours after the live presentation for 90 days after the event. About LivaNova
Delivered high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion Raised full-year 2025 revenue guidance; updated full-year 2025 guidance now incorporates impact of SNIA decision and currently applicable tariffs Completed premarket approval submission for the aura6000™ System intended to treat obstructive sleep apnea Announced 12-month, top-line OSPREY data demonstrating strong response and sustained therapeutic impact for patients who received proximal hypoglossal nerve stimulation for obstructive sleep apnea LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the first quarter
Top-line results at 12 months of treatment show meaningful improvement over time: Overall responder rate of 65% Overall reduction in median apnea-hypopnea index of 68% Overall reduction in median oxygen desaturation index of 68% LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced 12-month, top-line data from its OSPREY randomized controlled trial (RCT), evaluating outcomes with the aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). At 12 months of therapy, the treatment arm responder rate was 65% with responders defined as those who realized at least a 50% improvement from the baseline apnea-hypopnea index (AHI) and
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2025 results on Wednesday, May 7, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 047836. A replay will be available on the LivaN
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance. Financial Summary and Highlights(1) Fourth-quarter revenue of $321.8 million increased 3.8% on a reported basis, 4.7% on a constant-currency basis, and 6.8% on an organic basis as compared to the prior-year period Fourth-quarter U.S. GAAP diluted earnings per share of $1.02 and adjusted diluted earnings per share of $0.81 Full-year 2024 revenue of $1.25 billion increased 8.7% on a reported basis, 9.3% on a constant-currency basis, and 10.7% on an organic basis as compared to the prior-year Full-year 2024 U.S. GAAP
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The presentation will take place at 2:00 p.m. Eastern Time on Tuesday, March 11. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the webcast. A replay will be available on the LivaNova website within 24 hours after the live presentation for 90 days after the event. About Liva
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results on Tuesday, February 25, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2024 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 982570. A re
S-8 - LivaNova PLC (0001639691) (Filer)
8-K - LivaNova PLC (0001639691) (Filer)
SD - LivaNova PLC (0001639691) (Filer)
8-K - LivaNova PLC (0001639691) (Filer)
SCHEDULE 13G/A - LivaNova PLC (0001639691) (Subject)
IRANNOTICE - LivaNova PLC (0001639691) (Filer)
10-Q - LivaNova PLC (0001639691) (Filer)
8-K - LivaNova PLC (0001639691) (Filer)
DEFA14A - LivaNova PLC (0001639691) (Filer)
DEF 14A - LivaNova PLC (0001639691) (Filer)